Race Oncology (ASX: RAC) — Stock Profile

Racura Oncology Ltd is a Phase 3 clinical-stage biopharmaceutical company focused on cancer care, operating primarily through the development of small molecule anticancer agents. Its lead asset, RCDS1, also known as E,E-bisantrene, works principally through G4-DNA and RNA binding to achieve potent inhibition of MYC, a key regulator of cancer growth. The company is advancing a proprietary formulation of RCDS1, designated RC220, across multiple oncology indications, with active programs spanning a Phase 3 study in acute myeloid leukaemia, a Phase 1a/b study in mutant epidermal growth factor receptor non-small cell lung cancer, and a Phase 1a/b combination study with the anthracycline doxorubicin.

Racura's clinical development is supported by collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong, and the University of Newcastle. The company was formerly known as Race Oncology Ltd before adopting its current name in December 2025. Incorporated in 2011, Racura Oncology Ltd is headquartered in Sydney, Australia.